SMTL ID : 5oc8.1

HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.56 Å

Oligo State

monomer

Ligands

1 x 9QW: (4~{S})-5-(5-chloranyl-1-methyl-2-oxidanylidene-pyridin-3-yl)-4-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one(Non-covalent)

9QW.1: 13 residues within 4Å: Chain A: Q.9, L.39, L.42, G.43, I.46, M.47, Y.52, Q.57, F.71, V.78, H.81, I.84, Y.85 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:I.46, A:I.46, A:V.78, A:I.84 Water bridges: A:K.79, A:K.79 pi-Stacking: A:H.81 Halogen bonds: A:H.81

1 x CL: CHLORIDE ION(Non-functional Binders)

CL.2: 4 residues within 4Å: Chain A: Y.45, K.49, D.65, L.66 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Jeay, S. et al., Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. Cancer Res. (2018)

Release Date

2018-08-22

Peptides

E3 ubiquitin-protein ligase Mdm2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

E3 ubiquitin-protein ligase Mdm2

Related Entries With Identical Sequence